These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 2172592)

  • 1. [Effect of low molecular weight heparin on the hemodialysis model in dogs].
    Hamano S; Sakuragawa N
    Rinsho Byori; 1990 Jul; Suppl 86():165-70. PubMed ID: 2172592
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effects of low molecular weight heparin as an anti-coagulant for hemodialysis].
    Akizawa T; Kanamori N; Koshikawa S
    Rinsho Byori; 1990 Jul; Suppl 86():171-6. PubMed ID: 2172593
    [No Abstract]   [Full Text] [Related]  

  • 3. [Anticoagulation in hemodialysis with a single dose of low molecular weight heparin].
    Vukusich A; Avalos C; Orellana G; Cifuentes C; Rivas J; Calderón F
    Rev Med Chil; 1995 Jun; 123(6):735-41. PubMed ID: 8525227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute effect of standard heparin versus low molecular weight heparin on oxidative stress and inflammation in hemodialysis patients.
    Poyrazoglu OK; Dogukan A; Yalniz M; Seckin D; Gunal AL
    Ren Fail; 2006; 28(8):723-7. PubMed ID: 17162433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs.
    Minamiguchi K; Kitazato KT; Sasaki E; Nagase H; Kitazato K
    Thromb Haemost; 1997 Jun; 77(6):1148-53. PubMed ID: 9241748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipolytic effects of heparin and low molecular weight heparin and their importance in hemodialysis.
    Schrader J; Andersson LO; Armstrong VW; Kundt M; Stibbe W; Scheler F
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():41-5. PubMed ID: 1962903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients.
    Moia M; Graziani G; Tenconi PM; Martinelli I; Ponticelli C
    Ann Ital Med Int; 1997; 12(2):67-71. PubMed ID: 9284597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes in coagulation, fibrinolysis and platelet functions during extracorporeal circulation].
    Kaizu K; Uriu K; Ikeda M
    Nihon Rinsho; 2004 May; 62 Suppl 5():46-9. PubMed ID: 15197886
    [No Abstract]   [Full Text] [Related]  

  • 9. About the effect of low-molecular-weight heparin on platelet function in haemodialysis patients.
    Eleftheriadis T; Antoniadi G; Liakopoulos V; Stefanidis I
    Nephrol Dial Transplant; 2009 Mar; 24(3):1063-4. PubMed ID: 19131348
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and efficacy anticoagulation in extracorporeal hemodialysis by simultaneous administration of low-dose prostacyclin and low molecular weight heparin.
    Camici M; Giordani R; Morelli E; Meriggioli M; Balestri PL; Barsotti G; Sagripanti A
    Minerva Med; 1998; 89(11-12):405-9. PubMed ID: 10212664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of low-molecular weight heparin during hemodialysis].
    Kalinowski M; Pawlak K; Myśliwiec M; Popławski A
    Pol Merkur Lekarski; 1997 Jan; 2(9):208-10. PubMed ID: 10907031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview: from heparin to low molecular weight heparin: beyond anticoagulation.
    Mousa SA; Fareed J
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1077-80. PubMed ID: 11892916
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients.
    Brown JR; Kuter DJ
    Thromb Haemost; 2001 Jun; 85(6):979-85. PubMed ID: 11434705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of anticoagulation efficacy and clinical safety between imported and domestically manufactured low-molecular-weight heparin during hemodialysis.
    Liu ZQ; Wang L
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Oct; 22(10):942-3. PubMed ID: 12377628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Present opinions concerning the administration of low molecular weight heparins in hemodialysis patients].
    Drozdz M; Kowalczyk-Michałek M; Kraśniak A; Sułowicz W
    Przegl Lek; 2005; 62(4):257-9. PubMed ID: 16229247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparin for routine hemodialysis.
    Davenport A
    Hemodial Int; 2008 Oct; 12 Suppl 2():S34-7. PubMed ID: 18837768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of low-molecular-weight and unfractionated heparin on trophoblast function.
    Quenby S; Mountfield S; Cartwright JE; Whitley GS; Vince G
    Obstet Gynecol; 2004 Aug; 104(2):354-61. PubMed ID: 15292011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative study of low molecular weight heparin and unfractionated heparin in patients on maintenance hemodialysis].
    Noguchi M; Izumi K; Deguchi K; Endoh T; Tsuda M; Shirakawa S
    Rinsho Byori; 1990 Jul; Suppl 86():177-83. PubMed ID: 2172594
    [No Abstract]   [Full Text] [Related]  

  • 19. The safety of heparins in end-stage renal disease.
    Sonawane S; Kasbekar N; Berns JS
    Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epidemiology of anticoagulation for hemodialysis patients: survey of 842 cases in seven hemodialysis centers].
    Sun XF; Xiao Q; Wang Y; Hao LR; Lin HL; Zhang ZM; Li JJ; Chen XM
    Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(9):577-81. PubMed ID: 19595154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.